Gregory H. Reaman

27.9k total citations · 6 hit papers
306 papers, 15.8k citations indexed

About

Gregory H. Reaman is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Gregory H. Reaman has authored 306 papers receiving a total of 15.8k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Public Health, Environmental and Occupational Health, 130 papers in Pediatrics, Perinatology and Child Health and 72 papers in Oncology. Recurrent topics in Gregory H. Reaman's work include Acute Lymphoblastic Leukemia research (143 papers), Childhood Cancer Survivors' Quality of Life (112 papers) and Neuroblastoma Research and Treatments (52 papers). Gregory H. Reaman is often cited by papers focused on Acute Lymphoblastic Leukemia research (143 papers), Childhood Cancer Survivors' Quality of Life (112 papers) and Neuroblastoma Research and Treatments (52 papers). Gregory H. Reaman collaborates with scholars based in United States, Switzerland and Canada. Gregory H. Reaman's co-authors include Mark Krailo, Paul S. Gaynon, Nita L. Seibel, Malcolm A. Smith, David G. Poplack, Fatih M. Uckun, Sean F. Altekruse, Harland N. Sather, Bruce M. Camitta and Peter C. Adamson and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Gregory H. Reaman

299 papers receiving 15.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group

2012 814 citations Stephen P. Hunger, Meenakshi Devidas et al. Journal of Clinical Oncology profile →
Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century

2010 744 citations Malcolm A. Smith, Nita L. Seibel et al. Journal of Clinical Oncology profile →
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.

1995 594 citations Gregory H. Reaman et al. profile →
Declining childhood and adolescent cancer mortality

2014 363 citations Malcolm A. Smith, Gregory H. Reaman et al. Cancer profile →
American Society of Clinical Oncology Statement: Achieving High-Quality Cancer Survivorship Care

2013 353 citations Gregory H. Reaman et al. Journal of Clinical Oncology profile →
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia

2017 334 citations Gregory H. Reaman et al. profile →

Peers

Countries citing papers authored by Gregory H. Reaman

Since Specialization

Citations

This map shows the geographic impact of Gregory H. Reaman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory H. Reaman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory H. Reaman more than expected).

Fields of papers citing papers by Gregory H. Reaman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory H. Reaman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory H. Reaman. The network helps show where Gregory H. Reaman may publish in the future.

Co-authorship network of co-authors of Gregory H. Reaman

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory H. Reaman. A scholar is included among the top collaborators of Gregory H. Reaman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory H. Reaman. Gregory H. Reaman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development 2023 ·JNCI Journal of the National Cancer Institute ·Andrew D.J. Pearson, Teresa de Rojas, Dominik Karres, Gregory H. Reaman, Nicole Scobie, Elizabeth Fox, Giovanni Lesa, Franca Ligas, Koen Norga, Karsten Nysom, Alberto S. Pappo, Brenda J. Weigel, Susan Weiner, Gilles Vassal	1
2	Clinical trial considerations for pediatric cancer drug development 2023 ·Journal of Biopharmaceutical Statistics ·(unknown), Jingjing Ye, Gregory H. Reaman	0
3	The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology 2021 ·Clinical Cancer Research ·Julie A. Schneider, Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri‐Kordestani, Julia A. Beaver, Lola A. Fashoyin‐Aje, Nicole Gormley, (unknown), Steven J. Lemery, Pallavi S. Mishra‐Kalyani, Gregory H. Reaman, Donna R. Rivera, Wendy S. Rubinstein, Harpreet Singh, Rajeshwari Sridhara, Richard Pazdur	1
4	Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology 2021 ·Cancer Medicine ·David S. Shulman, (unknown), Stacey L. Edwards, Catherine Clinton, Sarah K. Hunt, (unknown), (unknown), Gregory H. Reaman, Hasan Al‐Sayegh, Kira Bona, Allison F. O’Neill, Suzanne Shusterman, Katherine A. Janeway, Andrew E. Place, Susan Chi, Clement Ma, Steven G. DuBois	6
5	Common Commentary on Paediatric Oncology Drug Development Published: Another Step in Optimising Global Regulatory Coordination of Paediatric Development Plans 2021 ·Therapeutic Innovation & Regulatory Science ·Dominik Karres, Gregory H. Reaman, Franca Ligas, Giovanni Lesa, Susan McCune, (unknown), Ralph Bax, Jean Temeck	4
6	Prevention of cisplatin‐induced hearing loss in children: Informing the design of future clinical trials 2018 ·Cancer Medicine ·Lori M. Minasian, A. Lindsay Frazier, Lillian Sung, Ann M. O’Mara, Joseph Kelaghan, Kay W. Chang, Mark Krailo, Brad H. Pollock, Gregory H. Reaman, David R. Freyer	15
7	Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Minimum Age Working Group 2017 ·Journal of Clinical Oncology ·Lia Gore, S. Percy Ivy, Frank M. Balis, Eric H. Rubin, Katherine A. Thornton, Martha Donoghue, Samantha Roberts, Suanna S. Bruinooge, Jennifer L. Ersek, Nancy Goodman, Caroline Schenkel, Gregory H. Reaman	50
8	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia 2010 ·Blood ·Richard C. Harvey, Charles G. Mullighan, I‐Ming Chen, Walker Wharton, Fady M. Mikhail, Andrew J. Carroll, Huining Kang, Wei Liu, Kevin K. Dobbin, Malcolm A. Smith, William L. Carroll, Meenakshi Devidas, W. Paul Bowman, Bruce M. Camitta, Gregory H. Reaman, Stephen P. Hunger, James R. Downing, Cheryl L. Willman	395
9	A Pharmacoeconomic Analysis of Pegaspargase Versus Native Escherichia Coli l-Asparaginase for the Treatment of Children With Standard-Risk, Acute Lymphoblastic Leukemia: The Children's Cancer Group Study (CCG-1962) 2002 ·Journal of Pediatric Hematology/Oncology ·(unknown), Alice G. Ettinger, David L. Veenstra, Paul S. Gaynon, Janet Franklin, Susan Sencer, Gregory H. Reaman, Beverly J. Lange, John S. Holcenberg	38
10	Phase I Trial of Cisplatin and Topotecan in Children With Recurrent Solid Tumors: Children's Cancer Group Study 0942 2002 ·The American journal of pediatric hematology/oncology ·Robert J. Wells, Joel M. Reid, Matthew M. Ames, (unknown), Mark Krailo, Nita L. Seibel, Revonda B. Mosher, Gregory H. Reaman, Susan R. Wiersma	13
11	Prospective Randomized Trial Between Two Doses of Granulocyte Colony-Stimulating Factor After Ifosfamide, Carboplatin, and Etoposide in Children With Recurrent or Refractory Solid Tumors: A Children's Cancer Group Report 2001 ·The American journal of pediatric hematology/oncology ·Mitchell S. Cairo, Violet Shen, Mark Krailo, Madeline Bauer, James S. Miser, Judith K. Sato, Julie Blatt, Bruce R. Blazar, Sharon Frierdich, Wen Liu‐Mares, Gregory H. Reaman	45
12	Prognostic Factors and Secondary Malignancies in Childhood Medulloblastoma 2001 ·The American journal of pediatric hematology/oncology ·Theodora Stavrou, Christina M. Bromley, H. Stacy Nicholson, Julianne Byrne, Roger J. Packer, Alisa M. Goldstein, Gregory H. Reaman	79
13	Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies 1998 ·Cancer ·Fatih M. Uckun, James B. Nachman, Harland N. Sather, Martha G. Sensel, Peter Kraft, Peter G. Steinherz, Beverly Lange, Raymond J. Hutchinson, Gregory H. Reaman, Paul S. Gaynon, Nyla A. Heerema	1
14	Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia: A Childrens Cancer Group/National Institutes of Health report 1996 ·Cancer ·Lisa B. Kenney, H. Stacy Nicholson, Cynthia Brasseux, James L. Mills, Leslie L. Robison, Lonnie K. Zeltzer, Anna T. Meadows, Gregory H. Reaman, Julianne Byrne	37
15	Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia: A Childrens Cancer Group/National Institutes of Health report 1996 ·Cancer ·Lisa B. Kenney, H. Stacy Nicholson, Cynthia Brasseux, James L. Mills, Leslie L. Robison, Lonnie K. Zeltzer, Anna T. Meadows, Gregory H. Reaman, Julianne Byrne	2
16	Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. 1992 ·Journal of Clinical Investigation ·Carolyn A. Felix, D D’Amico, Tetsuya Mitsudomi, Marion M. Nau, (unknown), Joseph F. Fraumeni, Diane E. Cole, (unknown), Gregory H. Reaman, J. Whang‐Peng	34
17	A Phase I Study of Interleukin-2 in Children with Cancer 1992 ·Journal of Pediatric Hematology/Oncology ·(unknown), Malcolm A. Smith, Paul M. Sondel, Andrea Gillespie, Gregory H. Reaman, G. Denman Hammond, Daniel Levitt, Angelo Rosolen, Oscar R. Colamonici, Len Neckers, David G. Poplack	23
18	Phase I trial and pharmacokinetic evaluation of fazarabine in children. 1989 ·PubMed ·Richard L. Heideman, Andrea Gillespie, Harry Ford, Gregory H. Reaman, Frank M. Balis, Charlotte Tan, (unknown), Lawrence J. Ettinger, Roger J. Packer, David G. Poplack	18
19	Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. 1989 ·PubMed ·Richard L. Heideman, Diane E. Cole, Frank M. Balis, (unknown), Gregory H. Reaman, Roger J. Packer, (unknown), Lawrence J. Ettinger, Andy Gillespie, Johannes Sam	111
20	Late soft tissue recurrence of acute lymphoblastic leukemia in a site of antecedent trauma 1978 ·The Journal of Pediatrics ·Gregory H. Reaman, David G. Poplack, Philip A. Pizzo	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact